{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:27:29Z","timestamp":1782602849373,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jhep.2020.12.025","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:14:03Z","timestamp":1610590443000},"page":"977-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Yet more evidence that MAFLD is more than a name change"],"prefix":"10.1016","volume":"74","author":[{"given":"Mohammed","family":"Eslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-5476","authenticated-orcid":false,"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.12.025_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jhep.2020.10.019","article-title":"Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR_based lipoprotein profiling","volume":"74","author":"Xia","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.jhep.2020.12.025_bib3","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhep.2020.12.025_bib4","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2020.07.008","article-title":"Letter regarding \u201cA new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement\u201d","volume":"73","author":"Mak","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib5","first-page":"154433","article-title":"MAFLD and risk of CKD","author":"Sun","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jhep.2020.12.025_bib6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jhep.2020.07.045","article-title":"Reply to: correspondence regarding \"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement\": bringing evidence to the NAFLD-MAFLD debate","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.12.025_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.14739","article-title":"The NAFLD-MAFLD debate: eminence versus evidence","volume":"41","author":"Fouad","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.12.025_bib8","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol H"},{"key":"10.1016\/j.jhep.2020.12.025_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2020.10.015","article-title":"Non-alcoholic fatty liver disease: not time for an obituary just yet!","volume":"74","author":"Singh","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2020.12.025_bib11","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.12.025_bib12","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.510360543","article-title":"Leave gourmandising","volume":"36","author":"Reuben","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.12.025_bib14","first-page":"379","article-title":"The diagnosis of exclusion: an ongoing uncertainty","volume":"40","author":"Fred","year":"2013","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.jhep.2020.12.025_bib15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ajg.2010.47","article-title":"Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts","volume":"105","author":"Spiegel","year":"2010","journal-title":"The Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.12.025_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/bmj.2.6138.653","article-title":"Towards positive diagnosis of the irritable bowel","volume":"2","author":"Manning","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.jhep.2020.12.025_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jhep.2020.12.025_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2020.12.025_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2020.12.025_bib20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.12.025_bib21","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/j.1572-0241.2003.07640.x","article-title":"Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome","volume":"98","author":"Sanyal","year":"2003","journal-title":"The Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.12.025_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1478-3231.2007.01482.x","article-title":"Impact of non-alcoholic fatty liver disease on chronic hepatitis B","volume":"27","author":"Bondini","year":"2007","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2020.12.025_bib23","doi-asserted-by":"crossref","first-page":"ofz509","DOI":"10.1093\/ofid\/ofz509","article-title":"Presumed nonalcoholic fatty liver disease among medicare beneficiaries with HIV, 2006\u20132016","volume":"7","author":"Paik","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jhep.2020.12.025_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.12.025_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.12.025_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","article-title":"The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease","volume":"6","author":"Mendez-Sanchez","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib27","first-page":"1","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.12.025_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clinre.2014.08.014","article-title":"Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: is it different?","volume":"39","author":"Singh","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhep.2020.12.025_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S2468-1253(20)30090-X","article-title":"Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health","volume":"5","author":"Eslam","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib30","first-page":"1","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","author":"Eslam","year":"2019","journal-title":"Nat Rev Gastro Hepat"},{"key":"10.1016\/j.jhep.2020.12.025_bib31","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"Liu","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2020.12.025_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jhep.2017.11.038","article-title":"The PNPLA3 SNP rs738409: G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort","volume":"68","author":"Meffert","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.12.025_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-06540-3","article-title":"Phenome-wide association studies across large population cohorts support drug target validation","volume":"9","author":"Diogo","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2020.12.025_bib34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.12.025_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.12.025_bib36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","article-title":"Genetic insights for drug development in NAFLD","volume":"40","author":"Eslam","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhep.2020.12.025_bib37","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","author":"Newsome","year":"2020","journal-title":"New Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:26Z","timestamp":1759174886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0168827821000088"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.12.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yet more evidence that MAFLD is more than a name change","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.10.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.10.019","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}